Published in J Clin Microbiol on June 01, 2004
Acute hemorrhagic pericarditis in a child with pneumonia due to Chlamydophila pneumoniae. J Clin Microbiol (2005) 1.02
Comparative Seroepidemiologic Analysis of Chlamydophila Pneumoniae Infection using Microimmunofluorescence, Enzyme Immunoassay and Neutralization Test: Implications for Serodiagnosis. Indian J Microbiol (2011) 0.84
A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis (1990) 6.52
Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol (1987) 4.53
The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med (1994) 2.92
Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis (2001) 2.71
Replicate PCR testing and probit analysis for detection and quantitation of Chlamydia pneumoniae in clinical specimens. J Clin Microbiol (2001) 2.59
Detection of Chlamydia pneumoniae by polymerase chain reaction. J Clin Microbiol (1992) 2.49
IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc Natl Acad Sci U S A (1987) 2.37
A seroepidemiologic study of Chlamydia pneumoniae in Rhode Island. Evidence of serologic cross-reactivity. Chest (1993) 2.09
Serological cross-reactions between Bartonella and Chlamydia species: implications for diagnosis. J Clin Microbiol (1997) 2.08
Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA (2002) 1.95
Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis (1993) 1.89
Specificity of the microimmunofluorescence assay for the serodiagnosis of Chlamydia pneumoniae infections. Can J Microbiol (1992) 1.77
Chlamydia pneumoniae and the lung. Eur Respir J (2000) 1.68
Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens. J Clin Microbiol (2001) 1.46
Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev (2002) 1.45
Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979. J Infect Dis (1992) 1.39
Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J Infect Dis (2000) 1.36
Chlamydia pneumoniae as a respiratory pathogen. Front Biosci (2002) 1.34
Evaluation of PCR, culture, and serology for diagnosis of Chlamydia pneumoniae respiratory infections. J Clin Microbiol (1998) 1.21
Occurrence of antibodies against chlamydial lipopolysaccharide in human sera as measured by ELISA using an artificial glycoconjugate antigen. FEMS Immunol Med Microbiol (1994) 1.20
Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2 cells. Infect Immun (2001) 1.18
Chlamydia pneumoniae and atherosclerosis -- what we know and what we don't. Clin Microbiol Infect (2002) 1.15
The epidemiology and significance of Chlamydia pneumoniae. J Infect (1992) 1.10
Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review. BMC Infect Dis (2002) 1.09
Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals. J Clin Microbiol (2002) 0.97
Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur Respir J (2002) 0.97
Chlamydia pneumoniae infection of the central nervous system. Curr Opin Neurol (2001) 0.96
Is infection with Chlamydia pneumoniae a causative agent in atherosclerosis? Mol Med Today (1998) 0.94
Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae. Eur Heart J (1993) 0.94
Performance of three microimmunofluorescence assays for detection of Chlamydia pneumoniae immunoglobulin M, G, and A antibodies. Clin Diagn Lab Immunol (2002) 0.93
Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. Antimicrob Agents Chemother (2002) 0.92
Ultrastructural study of Chlamydia pneumoniae in a continuous-infection model. J Clin Microbiol (2001) 0.90
Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J Antimicrob Chemother (2002) 0.85
CD36 is a sensor of diacylglycerides. Nature (2005) 5.20
Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol (2004) 3.13
Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem (2006) 2.90
Enhanced antiinflammatory capacity of a Lactobacillus plantarum mutant synthesizing modified teichoic acids. Proc Natl Acad Sci U S A (2005) 2.82
A multicenter trial to compare blood culture with polymerase chain reaction in severe human sepsis. Intensive Care Med (2009) 2.60
Innate immunity in Arabidopsis thaliana: lipopolysaccharides activate nitric oxide synthase (NOS) and induce defense genes. Proc Natl Acad Sci U S A (2004) 2.40
Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health (2009) 2.21
Attributable costs of patients with candidemia and potential implications of polymerase chain reaction-based pathogen detection on antifungal therapy in patients with sepsis. J Crit Care (2012) 2.11
Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J Exp Med (2002) 1.93
Prevalence of Borrelia burgdorferi sensu lato genospecies in Ixodes ricinus ticks in Europe: a metaanalysis. Appl Environ Microbiol (2005) 1.71
L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. J Immunol (2004) 1.70
High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR. J Mol Med (Berl) (2003) 1.66
Cellular trafficking of lipoteichoic acid and Toll-like receptor 2 in relation to signaling: role of CD14 and CD36. J Leukoc Biol (2008) 1.61
"ToxRTool", a new tool to assess the reliability of toxicological data. Toxicol Lett (2009) 1.54
Differential recognition of TLR-dependent microbial ligands in human bronchial epithelial cells. J Immunol (2007) 1.53
Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol (2005) 1.49
mRNA expression is a relevant tool to identify developmental neurotoxicants using an in vitro approach. Toxicol Sci (2009) 1.49
Structural decomposition and heterogeneity of commercial lipoteichoic Acid preparations. Infect Immun (2002) 1.46
Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia. J Infect Dis (2003) 1.44
Co-infection with two Chlamydophila species in a case of fulminant myocarditis. Crit Care Med (2007) 1.43
Lateral diffusion of Toll-like receptors reveals that they are transiently confined within lipid rafts on the plasma membrane. J Cell Sci (2004) 1.41
Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein-Barr virus DNAemia. Leuk Lymphoma (2012) 1.40
Lipopolysaccharide- and lipoteichoic acid-induced tolerance and cross-tolerance: distinct alterations in IL-1 receptor-associated kinase. J Immunol (2002) 1.39
Role of lipoteichoic acid in the phagocyte response to group B streptococcus. J Immunol (2005) 1.35
Differential effects of CpG-DNA in Toll-like receptor-2/-4/-9 tolerance and cross-tolerance. Immunology (2005) 1.34
Cytokine induction by purified lipoteichoic acids from various bacterial species--role of LBP, sCD14, CD14 and failure to induce IL-12 and subsequent IFN-gamma release. Eur J Immunol (2002) 1.34
Coronary microembolization: the role of TNF-alpha in contractile dysfunction. J Mol Cell Cardiol (2002) 1.32
Lipoteichoic acid and toll-like receptor 2 internalization and targeting to the Golgi are lipid raft-dependent. J Biol Chem (2004) 1.31
Superantigen-like gene(s) in human pathogenic Streptococcus dysgalactiae, subsp equisimilis: genomic localisation of the gene encoding streptococcal pyrogenic exotoxin G (speG(dys)). FEMS Immunol Med Microbiol (2002) 1.30
Highly purified lipoteichoic acid activates neutrophil granulocytes and delays their spontaneous apoptosis via CD14 and TLR2. J Leukoc Biol (2003) 1.29
Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis (2003) 1.28
Prevalence of hepatitis E virus-specific antibodies in humans with occupational exposure to pigs. Med Microbiol Immunol (2011) 1.28
Guidance on good cell culture practice. a report of the second ECVAM task force on good cell culture practice. Altern Lab Anim (2005) 1.27
Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol (2003) 1.26
Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies. Environ Health Perspect (2007) 1.26
Distribution of clinically relevant Borrelia genospecies in ticks assessed by a novel, single-run, real-time PCR. J Clin Microbiol (2002) 1.24
Toll-like receptor 4 (TLR4)-deficient murine macrophage cell line as an in vitro assay system to show TLR4-independent signaling of Bacteroides fragilis lipopolysaccharide. Infect Immun (2002) 1.21
Consensus report on the future of animal-free systemic toxicity testing. ALTEX (2014) 1.20
Mitogen-activated protein kinase-activated protein kinase 2-deficient mice show increased susceptibility to Listeria monocytogenes infection. J Immunol (2002) 1.19
Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. ALTEX (2013) 1.19
Functional analysis of D-alanylation of lipoteichoic acid in the probiotic strain Lactobacillus rhamnosus GG. Appl Environ Microbiol (2007) 1.17
Comparison of lipoteichoic acid from different serotypes of Streptococcus pneumoniae. J Biol Chem (2006) 1.17
Cytokine induction by Gram-positive bacteria. Immunobiology (2008) 1.15
A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing - t4 report*. ALTEX (2012) 1.15
Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch Toxicol (2013) 1.14
Structure/function relationships of lipoteichoic acids. J Endotoxin Res (2005) 1.13
Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. J Immunol (2008) 1.12
Evaluation of a polymerase chain reaction assay for pathogen detection in septic patients under routine condition: an observational study. PLoS One (2012) 1.12
Falciparum malaria after splenectomy: a prospective controlled study of 33 previously splenectomized Malawian adults. Trans R Soc Trop Med Hyg (2005) 1.11
D-alanylation of lipoteichoic acid contributes to the virulence of Streptococcus suis. Infect Immun (2008) 1.11
Definition of structural prerequisites for lipoteichoic acid-inducible cytokine induction by synthetic derivatives. J Immunol (2003) 1.10
Borrelia burgdorferi-induced tolerance as a model of persistence via immunosuppression. Infect Immun (2003) 1.10
Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. Liver Int (2009) 1.10
Cellular recognition of trimyristoylated peptide or enterobacterial lipopolysaccharide via both TLR2 and TLR4. J Biol Chem (2007) 1.09
Preoperative serum pattern analysis to predict the outcome of tonsillectomy in adults with chronic tonsillitis. Eur Arch Otorhinolaryngol (2014) 1.07
Chlamydial zoonoses. Dtsch Arztebl Int (2010) 1.07
t4 workshop report: Pathways of Toxicity. ALTEX (2013) 1.06
The dawning of a new age of toxicology. ALTEX (2008) 1.06
Induction of cytokine production in human T cells and monocytes by highly purified lipoteichoic acid: involvement of Toll-like receptors and CD14. Med Sci Monit (2002) 1.06
Inflammatory neurodegeneration induced by lipoteichoic acid from Staphylococcus aureus is mediated by glia activation, nitrosative and oxidative stress, and caspase activation. J Neurochem (2005) 1.06
Induction and regulation of endogenous granulocyte colony-stimulating factor formation. Biol Chem (2002) 1.05
A proposed eye irritation testing strategy to reduce and replace in vivo studies using Bottom-Up and Top-Down approaches. Toxicol In Vitro (2009) 1.04
Profound differences in leukocyte-endothelial cell responses to lipopolysaccharide versus lipoteichoic acid. J Immunol (2002) 1.03
Review: toxicometabolomics. J Appl Toxicol (2013) 1.03
Quality of Lyme disease serology. Lessons from the German Proficiency Testing Program 1999-2001. A preliminary report. Wien Klin Wochenschr (2002) 1.03
D-alanyl ester depletion of teichoic acids in Lactobacillus plantarum results in a major modification of lipoteichoic acid composition and cell wall perforations at the septum mediated by the Acm2 autolysin. J Bacteriol (2006) 1.02
A European perspective on alternatives to animal testing for environmental hazard identification and risk assessment. Regul Toxicol Pharmacol (2013) 1.02
Molecular interaction between lipoteichoic acids and Lactobacillus delbrueckii phages depends on D-alanyl and alpha-glucose substitution of poly(glycerophosphate) backbones. J Bacteriol (2007) 1.02
Diagnosis: toxic!--trying to apply approaches of clinical diagnostics and prevalence in toxicology considerations. Toxicol Sci (2005) 1.01
MDP and other muropeptides--direct and synergistic effects on the immune system. J Endotoxin Res (2006) 1.01
Gender difference in cytokine secretion on immune stimulation with LPS and LTA. J Interferon Cytokine Res (2006) 1.01
Direct analysis of clinical relevant single bacterial cells from cerebrospinal fluid during bacterial meningitis by means of micro-Raman spectroscopy. J Biophotonics (2009) 1.01
The use of ITS DNA sequence analysis and MALDI-TOF mass spectrometry in diagnosing an infection with Fusarium proliferatum. Exp Dermatol (2008) 1.01
Activation of neutrophils and inhibition of the proinflammatory cytokine response by endogenous granulocyte colony-stimulating factor in murine pneumococcal pneumonia. J Infect Dis (2004) 1.00
International validation of novel pyrogen tests based on human monocytoid cells. J Immunol Methods (2005) 0.99
Coexistence of pathogens in host-seeking and feeding ticks within a single natural habitat in Central Germany. Appl Environ Microbiol (2010) 0.99
Can the initial success of the Malawi ART scale-up programme be sustained? The example of Queen Elizabeth Central Hospital, Blantyre. AIDS Care (2007) 0.99
The Center for Alternatives to Animal Testing - Europe (CAAT-EU): a transatlantic bridge for the paradigm shift in toxicology. ALTEX (2010) 0.99
Lipoteichoic acid from Staphylococcus aureus is a potent stimulus for neutrophil recruitment. Immunobiology (2003) 0.98
Truncated human cytidylate-phosphate-deoxyguanylate-binding protein for improved nucleic acid amplification technique-based detection of bacterial species in human samples. J Clin Microbiol (2009) 0.98
Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use. Environ Health Perspect (2006) 0.98
The potential role of migratory birds in transmission cycles of Babesia spp., Anaplasma phagocytophilum, and Rickettsia spp. Ticks Tick Borne Dis (2010) 0.98
The principles of weight of evidence validation of test methods and testing strategies. The report and recommendations of ECVAM workshop 58. Altern Lab Anim (2006) 0.97
Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals. J Clin Microbiol (2002) 0.97
Heterozygous toll-like receptor 2 polymorphism does not affect lipoteichoic acid-induced chemokine and inflammatory responses. Infect Immun (2004) 0.97
Structural requirements of synthetic muropeptides to synergize with lipopolysaccharide in cytokine induction. J Biol Chem (2003) 0.97
The practical application of three validated in vitro embryotoxicity tests. The report and recommendations of an ECVAM/ZEBET workshop (ECVAM workshop 57). Altern Lab Anim (2006) 0.96
In vitro developmental neurotoxicity (DNT) testing: relevant models and endpoints. Neurotoxicology (2009) 0.96
Phyllanthus amarus has anti-inflammatory potential by inhibition of iNOS, COX-2, and cytokines via the NF-kappaB pathway. J Hepatol (2003) 0.96
CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J Pharmacol Exp Ther (2011) 0.96
Garlic (Allium sativum L.) modulates cytokine expression in lipopolysaccharide-activated human blood thereby inhibiting NF-kappaB activity. J Nutr (2003) 0.96
Food for thought... on cell culture. ALTEX (2007) 0.95
From "weight of evidence" to quantitative data integration using multicriteria decision analysis and Bayesian methods. ALTEX (2015) 0.95
Diagnosis of acute Q fever with emphasis on enzyme-linked immunosorbent assay and nested polymerase chain reaction regarding the time of serum collection. Diagn Microbiol Infect Dis (2010) 0.95